OR WAIT null SECS
Assistance Publique-Hôpitaux de Paris (AP-HP), Europe's clinical research center, joins IQVIA, the global health technology and human data science company, to launch the Paris Prime Site for clinical trials. This AP-HP partnership represents IQVIA’s second Prime Site within France, as well as the 43rd globally, the 18th within Europe and largest research facility of its kind within that region.
For IQVIA, the Prime Site designation assures its partner pharmaceutical and biotech companies that their clinical trials will take place in investigative research centers with recognized professionals and with infrastructure focused on innovation and research development for patients. IQVIA will provide staff entirely dedicated to AP-HP, including a Prime Site manager, who will oversee partnership relations and follow-up on the delivery of IQVIA research projects. AP-HP and IQVIA will collaborate on research programs to optimize processes, reduce the time to start clinical research, align procedures and support a significant increase in complex clinical trials and real-world evidence studies within France and Europe.
Florence Favrel-Feuillade, director of the Delegation for Clinical Research and Innovation, AP-HP, said, “The partnership between AP-HP and IQVIA is a strong signal of AP-HP's willingness to position itself as one of the world's leading reference centers for clinical investigation, particularly to enable patients to benefit from the most innovative treatments.”
Alistair Grenfell, president Europe, Middle East, and Africa, IQVIA, said, “The opening of the Paris Prime Site marks a significant milestone in the groundbreaking collaboration between IQVIA and AP-HP. By ensuring world class research, patients will have greater access to new innovative therapies and transformed health outcomes in the future.”
In 2018 AP-HP carried out more than 4,000 research projects, including 1,850 sponsored by industry and 1,240 sponsored by AP-HP. The GHU AP-HP Nord is particularly distinguished within the following fields: neuroscience, hematology, immunology, oncology, dermatology, gastro-intestinal diseases, infectious diseases, inflammatory and renal transplantation diseases, cardiovascular diseases, imaging and emergency care. The alliance between AP-HP and IQVIA will increase the visibility of Europe's largest university hospitals at an international level, particularly among biotech companies specializing in biotechnology across North America and Asia.